187 related articles for article (PubMed ID: 37200246)
1. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors.
Gottlieb J; Fischer B; Schupp JC; Golpon H
PLoS One; 2023; 18(5):e0284653. PubMed ID: 37200246
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
3. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
4. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
5. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
[TBL] [Abstract][Full Text] [Related]
6. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
Groetzner J; Wittwer T; Kaczmarek I; Ueberfuhr P; Strauch J; Nagib R; Meiser B; Franke U; Reichart B; Wahlers T
Transplantation; 2006 Feb; 81(3):355-60. PubMed ID: 16477220
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
9. Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.
Ivulich S; Paul E; Kirkpatrick C; Dooley M; Snell G
Transpl Int; 2023; 36():10704. PubMed ID: 36744051
[TBL] [Abstract][Full Text] [Related]
10. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.
Goralczyk AD; Schnitzbauer A; Tsui TY; Ramadori G; Lorf T; Obed A
BMC Surg; 2010 Apr; 10():15. PubMed ID: 20380712
[TBL] [Abstract][Full Text] [Related]
11. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
12. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
Chhabra D; Alvarado A; Dalal P; Leventhal J; Wang C; Sustento-Reodica N; Najafian N; Skaro A; Levitsky J; Mas V; Gallon L
Am J Transplant; 2013 Nov; 13(11):2902-11. PubMed ID: 24007570
[TBL] [Abstract][Full Text] [Related]
13. Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
Buchholz BM; Ferguson JW; Schnitzbauer AA; Nightingale P; Schlitt HJ; Geissler EK; Mirza DF;
Transplantation; 2020 May; 104(5):1003-1018. PubMed ID: 31577671
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
15. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients.
Rosenthal LM; Nordmeyer J; Kramer P; Danne F; Pfitzer C; Berger F; Schmitt KRL; Schubert S
Pediatr Transplant; 2021 Dec; 25(8):e14111. PubMed ID: 34405495
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
[TBL] [Abstract][Full Text] [Related]
18. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
Gottlieb J; Neurohr C; Müller-Quernheim J; Wirtz H; Sill B; Wilkens H; Bessa V; Knosalla C; Porstner M; Capusan C; Strüber M
Am J Transplant; 2019 Jun; 19(6):1759-1769. PubMed ID: 30615259
[TBL] [Abstract][Full Text] [Related]
20. Mammalian Target of Rapamycin Inhibitors and Kidney Function After Thoracic Transplantation: A Systematic Review and Recommendations for Management of Lung Transplant Recipients.
Schmucki K; Hofmann P; Fehr T; Inci I; Kohler M; Schuurmans MM
Transplantation; 2023 Jan; 107(1):53-73. PubMed ID: 36508646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
